Posted by Sonny Liston on December 30, 2005, at 18:44:17
In reply to Re: Effexor metabolite submitted for FDA approval, posted by law663 on December 30, 2005, at 17:41:08
According to Pharmatimes, "studies presented at the American Society for Clinical Pharmacology and Therapeutics earlier this year showed that the sustained-release formulation of desvenlafaxine leads to higher blood levels of the active drug than the once-daily Effexor XR/ER formulation of venlafaxine, and had a lower tendency to cause nausea."
These are the main reported "advantages" over Effexor. Not much to write home about about.
In addition Pharmatimes notes "that desvenlafaxine is seen as a patent extension strategy for Wyeth as it defends its Effexor franchise."
poster:Sonny Liston
thread:591573
URL: http://www.dr-bob.org/babble/20051221/msgs/593537.html